Biotech Values

[rstor1]

DNDN

The PR is incomplete, but they are presenting at JPMorgan, so that should fill in the blanks.

IMHO, the market completely misunderstood the PR. The name of the trial is similar to the ongoing PIII, and the 9902A has been almost hidden. Because of the underpowering, I doubt any conclusions can be drawn, and I am a bit disappointed that they are spining this into some kind of confirmation of 9901.

I am convinced that DNDN thought this would be a boost going into the conference. Talk about a fumble.

I bought more in the 7.60's - closed my ALNY short becasue I wanted buying power.

Regards,
Bob